Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.

Gupta A, Mehta R, Alimirah F, Peng X, Murillo G, Wiehle R, Mehta RG.

J Steroid Biochem Mol Biol. 2013 Jan;133:30-42. doi: 10.1016/j.jsbmb.2012.08.004.

PMID:
22939887
2.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE.

Int J Oncol. 2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850.

4.

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.

Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, Yue B, Serrero G.

BMC Cancer. 2011 Jun 9;11:231. doi: 10.1186/1471-2407-11-231.

5.

[Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].

Chen HY, Liu ZH.

Zhonghua Zhong Liu Za Zhi. 2013 Jun;35(6):423-8. Chinese.

PMID:
24119901
6.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

7.

Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.

Moy I, Lin Z, Rademaker AW, Reierstad S, Khan SA, Bulun SE.

PLoS One. 2013 Nov 6;8(11):e77543. doi: 10.1371/journal.pone.0077543.

8.

Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.

Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S.

Mol Cancer Res. 2005 Apr;3(4):203-18.

9.

The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.

Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S.

Breast Cancer Res Treat. 2010 Nov;124(1):89-99. doi: 10.1007/s10549-009-0716-3.

10.

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.

Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S.

Cancer Res. 2008 Jun 15;68(12):4910-8. doi: 10.1158/0008-5472.CAN-08-0303.

11.

Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.

Wang J, Gildea JJ, Yue W.

Oncogene. 2013 Oct 31;32(44):5233-40. doi: 10.1038/onc.2012.558.

PMID:
23178495
12.

Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

Dabydeen SA, Kang K, Díaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, Al-Kharboosh R, Clarke R, Hennighausen L, Furth PA.

Carcinogenesis. 2015 Jan;36(1):122-32. doi: 10.1093/carcin/bgu237.

13.

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

Evans AH, Pancholi S, Farmer I, Thornhill A, Evans DB, Johnston SR, Dowsett M, Martin LA.

Br J Cancer. 2010 Apr 13;102(8):1235-43. doi: 10.1038/sj.bjc.6605641.

14.

Aromatase and breast cancer.

Brodie A, Sabnis G, Jelovac D.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102.

15.
16.

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.

Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA.

Breast Cancer Res. 2015 Jan 30;17:13. doi: 10.1186/s13058-015-0515-1.

17.

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.

Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH.

Breast Cancer Res. 2014 Jan 29;16(1):R15. doi: 10.1186/bcr3609.

18.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.

Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330.

19.

Synergistic activity of letrozole and sorafenib on breast cancer cells.

Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, Petronini PG.

Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5.

PMID:
20054642
Items per page

Supplemental Content

Support Center